The Impact of Routine Molecular Screening for SARS-CoV-2 in Patients Receiving Anticancer Therapy: An Interim Analysis of the Observational COICA Study.

MLA

Di Lorenzo, Giuseppe, et al. “The Impact of Routine Molecular Screening for SARS-CoV-2 in Patients Receiving Anticancer Therapy: An Interim Analysis of the Observational COICA Study.” Oncology, vol. 100, no. 9, 2022, pp. 505–11. EBSCOhost, https://doi.org/10.1159/000521086.

APA

Di Lorenzo, G., Iervolino, M., Primiano, F., D’Ambrosio, M., Ingenito, C., Buonerba, L., Busto, G., Ferrara, C., Libroia, A., Ragone, G., De Falco, F., Costabile, F., Fimiani, P., Ugliano, F., Ranieri, C., Leo, E., Roviello, G., Scafuri, L., Guerra, G., & Buonerba, C. (2022). The Impact of Routine Molecular Screening for SARS-CoV-2 in Patients Receiving Anticancer Therapy: An Interim Analysis of the Observational COICA Study. Oncology, 100(9), 505–511. https://doi.org/10.1159/000521086

Chicago

Di Lorenzo, Giuseppe, Mario Iervolino, Ferdinando Primiano, Maurizio D’Ambrosio, Concetta Ingenito, Luciana Buonerba, Giuseppina Busto, et al. 2022. “The Impact of Routine Molecular Screening for SARS-CoV-2 in Patients Receiving Anticancer Therapy: An Interim Analysis of the Observational COICA Study.” Oncology 100 (9): 505–11. doi:10.1159/000521086.